 Mechlorethamine vincristine procarbazine chemotherapy recurrent high-grade glioma adults phase II study phase II study combination chemotherapy mechlorethamine nitrogen mustard day day vincristine mg day day days MOP adults recurrent high-grade glioma patients patients assessable response median age years old patients prior maximal radiotherapy previous chemotherapy Responses clinical computed tomographic CT scan/magnetic resonance imaging MRI criteria response rate partial response PR objective qualitative response OQR complete response CR CR response rate patients anaplastic astrocytoma glioblastoma multiforme median duration response weeks Median survival assessable patients weeks responders weeks Response ability dexamethasone doses improved performance status Toxicity hematologic leukopenia common treatment-related death listeria meningitis patients Pneumocystis carinii pneumonia episodes neutropenic fever MOP active merits investigation adult high-grade glioma